1.WHAT SCIENTISTS AT SYLVESTER COMPREHENSIVE CANCER CENTER DO AGAINST CANCER?
Scientists At Sylvester Comprehensive Cancer Center Collaborate With International Researchers To Perform Advanced Computational Analysis To Identify Potential Therapeutic Targets For Glioblastoma Multiforme (Gbm) And Other Cancers Developed Sophisticated Ai Algorithms. Her Research Describes Aggressive, Usually Fatal Types Of Brain Tumors, As Well As Certain Breast, Lung, And Childhood Cancers.

2.HOW SPHINKS DO SOMETHING AGAINST GBM?
An AI Algorithm Known As Sphinks (Substrate Phosphosite-based Inference For Networks Of Kinase S) Uses Deep Machine Learning To Help Researchers Link Two Protein Kinases (Pkcd And Dnapkcs) To Tumor Progression. We Helped To Classify As The Culprit Subtype And Experimentally Validate Gbm As A Potential Therapeutic Target For Other Cancers.

3.WHY SCIENTISTS BELIEVE IN SPHINKS?
Scientists Believe The Sphinks Approach Can Provide Insightful Information That Benefits Up To 75% Of Glioblastoma Patients. Sphinks Was First Tested In Glioblastoma, But The Algorithm Is Equally Applicable To Several Other Cancers. The Team Found The Same Cancer-causing Kinase In Breast, Lung, And Childhood Brain Tumors.
They Were Exploring The Concept Of Basket Trials, Which Would Include Patients With The Same Biological Subtype But Not Necessarily The Same Cancer Types. If Patients With Glioblastoma Or Breast Or Lung Cancer Have Similar Molecular Features, They Could Be Included In The Same Trial. Rather Than Doing Multiple Trials For A Single Agent, We Could Conduct One Combined Trial And Potentially Bring More Effective Drugs To More Patients Faster.